AffiliationDivision of Medical Oncology, Toronto-Sunnybrook Regional Cancer Centre, 2075 Bayview Avenue, Toronto, Ontario, Canada M4N 3M5. email@example.com
MetadataShow full item record
AbstractTamoxifen has been used in the management of breast cancer for over 30 years. Since its introduction for the treatment of advanced breast cancer, its indications have increased to include the treatment of early breast cancer, ductal carcinoma in situ, and more recently for breast cancer chemoprevention. Tamoxifen has a good tolerability profile and moreover, unlike many other endocrine therapies, it is efficacious in both pre- and postmenopausal women.It is the combination of efficacy and tolerability that allows tamoxifen to maintain its position as the hormonal treatment of choice for most patients with oestrogen-receptor positive breast cancer. Ongoing studies will provide further information about the optimal duration of tamoxifen therapy and how it compares with the newer aromatase inhibitors.
CitationTamoxifen ("Nolvadex"): a review. 2002, 28 (4):165-80 Cancer Treat. Rev.
JournalCancer Treatment Reviews
- Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
- Authors: Goss PE, Strasser K
- Issue date: 2002
- Aromatase inhibitors for breast cancer: pharmacoeconomic considerations.
- Authors: Higa GM
- Issue date: 2001 Jun
- Shifting paradigms in hormonal therapy for breast cancer.
- Authors: Grana G
- Issue date: 2004 Sep
- [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
- Authors: de Cremoux P, Diéras V, Poupon MF, Magdelénat H, Sigal-Zafrani B, Fourquet A, Pierga JY
- Issue date: 2004 Dec
- Biological rationale for endocrine therapy in breast cancer.
- Authors: Miller WR
- Issue date: 2004 Mar